IQVIA Holdings Inc. (IQV) fair value analysis
S&P 500 · Updated 2026-10-19
IQV price how computed
Forward Fair Value verdict
Fairly valuedIQV is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $259.88
- Sector
- Healthcare
- 12-month range
- $156.66–$275.02
- Market cap
- $42.8B
- From 52-week high
- -5.5%
- Shares outstanding
- 165M
- Rank in Healthcare by discount to fair value
- #51 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
IQVIA Holdings Inc. is a contract research organization that provides drug development, clinical trial management, and data analytics services to pharmaceutical, biotechnology, and medical device companies. The company operates globally with a presence across North America, Europe, Asia Pacific, and other international markets.
IQV currently ranks #51 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $42.8B
- P/E (trailing)
- 22x
- Revenue (TTM)
- $17B
- Net margin
- 8.1%
- EPS (TTM)
- $12.07
- Gross margin
- 32.9%
- Debt / equity
- 2.63
- Revenue growth (3-yr avg)
- 5.6%
- Shares outstanding
- 165M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 50 · neutral
- 50-day average
- $260.02
- 200-day average
- $207.74
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-27 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+1.1%)
2026-03 ▲ beat (+2.8%)
2025-12 ▲ beat (+0.6%)
2025-09 ▲ beat (+0.7%)
2025-06 ▲ beat (+1.4%)
2025-03 ▲ beat (+2.7%)
2024-12 ▲ beat (+0.3%)
2024-09 ▲ beat (+1.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 19 buy · 3 hold · 0 sell (22 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $299
- Target vs last price
- +15.1%
What our data shows for IQV
- Our model validated 17 trailing price-to-earnings windows for IQV, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $156.66–$275.02.
- The 14-day relative strength index sits at a neutral 50.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for IQV
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent IQV news
TickrTrends' derived news-sentiment signal for IQV is currently leaning positive, computed from recent coverage.
- Is IQVIA Holdings Inc (IQV) Overvalued After 3.3% Rally? GF Value Says Overvalued (gurufocus.com, 2026-10-21)
TickrTrends take: IQVIA Holdings operates in the Healthcare sector and TickrTrends currently assesses it as fairly valued, which contrasts with the headline's suggestion that recent gains have pushed it into overvalued territory. A valuation-focused reader should monitor whether the stock's momentum continues to accelerate or stabilizes, as this will help determine whether the current assessment holds or shifts toward the overvalued classification. The gap between TickrTrends' fairly valued rating and other valuation indicators like GF Value suggests investors should track fundamental metrics and earnings developments to clarify the stock's true pricing. - IQVIA Holdings Inc (IQV) -- Resilient Growth Amid Industry Demand | Artisan Global Value Q3 2026 (gurufocus.com, 2026-10-20)
TickrTrends take: IQVIA's resilient growth trajectory within a sector experiencing sustained industry demand provides a foundation supporting its current fairly valued assessment by TickrTrends. For valuation-focused investors, the key monitoring point centers on whether the company can maintain this growth momentum while managing margin expansion, as any meaningful deviation from current demand patterns could shift the valuation calculus. The Healthcare sector's structural tailwinds suggest the fairly valued positioning reflects appropriate pricing relative to IQV's earnings power, though tracking execution on revenue growth will remain critical to validating this assessment. - IQVIA: A $34.2 Billion Backlog Does Not Guarantee Faster Earnings Growth (NYSE:IQV) (seekingalpha.com, 2026-10-16)
TickrTrends take: IQVIA maintains a substantial backlog of contracted work, though the presence of such revenue visibility does not automatically translate into accelerated earnings expansion. The company's current valuation alignment as fairly valued suggests the market has already incorporated expectations around converting this backlog into profitability. Investors focused on valuation should monitor whether management can demonstrate margin expansion and efficient execution, as these factors will ultimately determine whether current pricing remains justified given the company's Healthcare sector positioning and growth trajectory.
More IQV news
- IQVIA Holdings Inc (IQV) Stock Up 3.5% but GF Value Says Overvalued -- GF Score: 92/100 (gurufocus.com, 2026-10-15)
- IQV Maintained by Stifel -- Price Target Raised to $303 (gurufocus.com, 2026-10-14)
- IQVIA Holdings Inc. (IQV) -- Strengthening Pharmaceutical Insights | Hardman Johnston Q3 2026 (gurufocus.com, 2026-10-11)
- IQVIA Holdings Inc. (IQV) -- Strengthening Pharmaceutical Insights | Hardman Johnston Q3 2026 (gurufocus.com, 2026-10-11)
- A Look at IQVIA Holdings Inc (IQV) After 3.0% Gain -- GF Value $249.70 vs Price $266.09 (gurufocus.com, 2026-10-05)
What people are saying
Follow the IQV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — IQV's quality grade improved from F to D this week, indicating a modest strengthening in the company's fundamental metrics. Despite this upgrade in quality assessment, TickrTrends' derived indicators continue to reflect a fairly valued position for the healthcare sector company.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — IQV's sector discount rank declined this week, moving from 66th to 71st place among Healthcare sector stocks. This shift indicates that IQV has become relatively less discounted compared to its Healthcare peers. The stock maintains a Fairly valued verdict overall.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is IQV stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), IQV is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is IQV's TickrTrends verdict?
IQV's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does IQV compare to other Healthcare stocks?
IQV ranks #51 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is IQV overbought or oversold?
IQV's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does IQV report earnings next?
IQV's next earnings report is scheduled for 2026-10-27 (pre-market), per the published earnings calendar.
Does IQV usually beat earnings estimates?
Over its last 8 reported quarters IQV beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about IQV?
Of 22 analysts covering IQV, 19 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $299 (+15.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
IQV vs DHR · IQV vs EXEL · IQV vs HCSG · IQV vs HSIC · IQV vs KNSA